Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
- 1 March 2014
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 28 (2), 75-86
- https://doi.org/10.1016/j.blre.2014.01.004
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor ResponsesClinical Cancer Research, 2012
- Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma PatientsJournal of Immunology Research, 2012
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipientsBlood, 2011
- Transfer of influenza vaccine–primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trialBlood, 2011
- Killing of Avian and Swine Influenza Virus by Natural Killer CellsJournal of Virology, 2010
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Community-Acquired Lung Abscess Caused by Legionella micdadei in a Myeloma Patient Receiving Thalidomide TreatmentJournal of Clinical Microbiology, 2007
- Natural regulatory T cells in infectious diseaseNature Immunology, 2005